Clearmind submits recommendations to FDA on future therapeutic use of psychedelic drugs
CMND•Clearmind submitted recommendations to the FDA on potential future therapeutic uses of psychedelic drugs, urging pathways for at-home use of non-hallucinogenic neuroplastogens for alcohol use disorder and expanded federal research partnerships.
1. Recommendations to FDA
Clearmind submitted recommendations under Docket FDA-2026-N-7542, urging regulatory pathways that could support at-home use of non-hallucinogenic neuroplastogens for alcohol use disorder. The company also pressed for expanded federal research partnerships, citing ongoing trials at Yale University and Johns Hopkins University.
